GSK shares down on news Blenrep unlikely to get US approval
Blenrep fails to impress US regulator Potential $1 billion sales hit Drug approved in UK and Japan GSK (GSK) was the biggest faller in the FTSE on Friday (18 July) after reporting that its blood cancer treatment Benrep received a...
18 July 2025